AAPL334.19+7.62 (+2.33%) ▲|ABBV257.58+2.58 (+1.01%) ▲|ABT102.30-1.07 (-1.03%) ▼|ACN181.42+3.51 (+1.97%) ▲|ADBE253.84+5.01 (+2.01%) ▲|AMAT461.61+7.60 (+1.67%) ▲|AMD515.91+12.31 (+2.44%) ▲|AMGN379.07-3.40 (-0.89%) ▼|AMT178.40+5.42 (+3.13%) ▲|AMZN256.82+4.93 (+1.96%) ▲|AVGO364.95+4.12 (+1.14%) ▲|AXP325.17+4.46 (+1.39%) ▲|BA210.76+5.96 (+2.91%) ▲|BAC62.93+0.37 (+0.59%) ▲|BKNG174.68+0.77 (+0.44%) ▲|BLK1,086.52+24.12 (+2.27%) ▲|BMY63.43-0.32 (-0.50%) ▼|BNY162.91+0.32 (+0.20%) ▲|BRK-B507.30+0.30 (+0.06%) ▲|C138.88+0.38 (+0.27%) ▲|CAT821.98+16.98 (+2.11%) ▲|CL87.62-0.28 (-0.32%) ▼|CMCSA25.27+0.10 (+0.38%) ▲|COF208.13+1.02 (+0.49%) ▲|COP136.51-0.53 (-0.39%) ▼|COST904.23+1.85 (+0.21%) ▲|CRM248.79+5.79 (+2.38%) ▲|CSCO111.61+4.17 (+3.88%) ▲|CVS94.34-0.96 (-1.00%) ▼|CVX213.94+1.18 (+0.55%) ▲|DE681.57+3.63 (+0.54%) ▲|DHR200.99+0.46 (+0.23%) ▲|DIS106.61+0.79 (+0.74%) ▲|DUK119.78+0.41 (+0.34%) ▲|EMR151.69+3.32 (+2.24%) ▲|FDX312.90+1.10 (+0.35%) ▲|GD357.12+2.87 (+0.81%) ▲|GE325.80+1.65 (+0.51%) ▲|GEV952.55+28.64 (+3.10%) ▲|GILD144.01-0.80 (-0.55%) ▼|GM86.45+0.33 (+0.38%) ▲|GOOG337.69+7.30 (+2.21%) ▲|GOOGL340.72+8.12 (+2.44%) ▲|GS1,031.89+12.12 (+1.19%) ▲|HD309.43+3.74 (+1.22%) ▲|HON202.80+0.62 (+0.30%) ▲|IBM240.68+6.66 (+2.85%) ▲|INTC103.37+3.05 (+3.04%) ▲|INTU320.00+7.23 (+2.31%) ▲|ISRG367.90+7.44 (+2.06%) ▲|JNJ265.75-0.61 (-0.23%) ▼|JPM356.59+3.03 (+0.86%) ▲|KO88.28+0.45 (+0.51%) ▲|LIN467.02+5.40 (+1.17%) ▲|LLY1,122.11-0.90 (-0.08%) ▼|LMT525.69-4.43 (-0.84%) ▼|LOW198.13+1.54 (+0.78%) ▲|LRCX301.69+3.68 (+1.23%) ▲|MA569.53+4.16 (+0.74%) ▲|MCD253.43+0.38 (+0.15%) ▲|MDLZ62.56+0.09 (+0.14%) ▲|MDT90.62-1.00 (-1.09%) ▼|META650.18+5.80 (+0.90%) ▲|MMM165.16+2.30 (+1.41%) ▲|MO69.10+0.31 (+0.45%) ▲|MRK145.37+0.66 (+0.45%) ▲|MS214.53+1.87 (+0.88%) ▲|MSFT495.34+2.90 (+0.59%) ▲|MU978.14+0.73 (+0.07%) ▲|NEE82.90+0.46 (+0.56%) ▲|NFLX77.06+1.05 (+1.37%) ▲|NKE36.94+0.32 (+0.87%) ▲|NOW132.97+1.80 (+1.37%) ▲|NVDA219.32+0.96 (+0.44%) ▲|ORCL152.94+0.00 (+0.00%) ▲|PEP137.04+0.39 (+0.29%) ▲|PFE27.61-0.05 (-0.16%) ▼|PG145.39+2.42 (+1.69%) ▲|PLTR167.09+1.23 (+0.74%) ▲|PM193.15+3.38 (+1.78%) ▲|QCOM185.31+8.43 (+4.76%) ▲|RTX198.37+0.25 (+0.13%) ▲|SBUX99.00-0.22 (-0.22%) ▼|SCHW106.81-0.53 (-0.49%) ▼|SO88.01+0.26 (+0.30%) ▲|SPG205.14+0.47 (+0.23%) ▲|T26.16+0.61 (+2.39%) ▲|TMO612.04+8.86 (+1.47%) ▲|TMUS183.56+6.40 (+3.61%) ▲|TSLA366.21+2.65 (+0.73%) ▲|TXN271.95+13.13 (+5.07%) ▲|UBER71.92-0.64 (-0.88%) ▼|UNH378.35-9.93 (-2.56%) ▼|UNP284.26-1.53 (-0.53%) ▼|UPS100.12+0.15 (+0.15%) ▲|USB62.83+0.42 (+0.67%) ▲|V371.12+3.91 (+1.06%) ▲|VZ50.63+0.66 (+1.32%) ▲|WFC90.52+1.07 (+1.19%) ▲|WMT106.62+0.89 (+0.84%) ▲|XOM165.55+0.32 (+0.19%) ▲|AAPL334.19+7.62 (+2.33%) ▲|ABBV257.58+2.58 (+1.01%) ▲|ABT102.30-1.07 (-1.03%) ▼|ACN181.42+3.51 (+1.97%) ▲|ADBE253.84+5.01 (+2.01%) ▲|AMAT461.61+7.60 (+1.67%) ▲|AMD515.91+12.31 (+2.44%) ▲|AMGN379.07-3.40 (-0.89%) ▼|AMT178.40+5.42 (+3.13%) ▲|AMZN256.82+4.93 (+1.96%) ▲|AVGO364.95+4.12 (+1.14%) ▲|AXP325.17+4.46 (+1.39%) ▲|BA210.76+5.96 (+2.91%) ▲|BAC62.93+0.37 (+0.59%) ▲|BKNG174.68+0.77 (+0.44%) ▲|BLK1,086.52+24.12 (+2.27%) ▲|BMY63.43-0.32 (-0.50%) ▼|BNY162.91+0.32 (+0.20%) ▲|BRK-B507.30+0.30 (+0.06%) ▲|C138.88+0.38 (+0.27%) ▲|CAT821.98+16.98 (+2.11%) ▲|CL87.62-0.28 (-0.32%) ▼|CMCSA25.27+0.10 (+0.38%) ▲|COF208.13+1.02 (+0.49%) ▲|COP136.51-0.53 (-0.39%) ▼|COST904.23+1.85 (+0.21%) ▲|CRM248.79+5.79 (+2.38%) ▲|CSCO111.61+4.17 (+3.88%) ▲|CVS94.34-0.96 (-1.00%) ▼|CVX213.94+1.18 (+0.55%) ▲|DE681.57+3.63 (+0.54%) ▲|DHR200.99+0.46 (+0.23%) ▲|DIS106.61+0.79 (+0.74%) ▲|DUK119.78+0.41 (+0.34%) ▲|EMR151.69+3.32 (+2.24%) ▲|FDX312.90+1.10 (+0.35%) ▲|GD357.12+2.87 (+0.81%) ▲|GE325.80+1.65 (+0.51%) ▲|GEV952.55+28.64 (+3.10%) ▲|GILD144.01-0.80 (-0.55%) ▼|GM86.45+0.33 (+0.38%) ▲|GOOG337.69+7.30 (+2.21%) ▲|GOOGL340.72+8.12 (+2.44%) ▲|GS1,031.89+12.12 (+1.19%) ▲|HD309.43+3.74 (+1.22%) ▲|HON202.80+0.62 (+0.30%) ▲|IBM240.68+6.66 (+2.85%) ▲|INTC103.37+3.05 (+3.04%) ▲|INTU320.00+7.23 (+2.31%) ▲|ISRG367.90+7.44 (+2.06%) ▲|JNJ265.75-0.61 (-0.23%) ▼|JPM356.59+3.03 (+0.86%) ▲|KO88.28+0.45 (+0.51%) ▲|LIN467.02+5.40 (+1.17%) ▲|LLY1,122.11-0.90 (-0.08%) ▼|LMT525.69-4.43 (-0.84%) ▼|LOW198.13+1.54 (+0.78%) ▲|LRCX301.69+3.68 (+1.23%) ▲|MA569.53+4.16 (+0.74%) ▲|MCD253.43+0.38 (+0.15%) ▲|MDLZ62.56+0.09 (+0.14%) ▲|MDT90.62-1.00 (-1.09%) ▼|META650.18+5.80 (+0.90%) ▲|MMM165.16+2.30 (+1.41%) ▲|MO69.10+0.31 (+0.45%) ▲|MRK145.37+0.66 (+0.45%) ▲|MS214.53+1.87 (+0.88%) ▲|MSFT495.34+2.90 (+0.59%) ▲|MU978.14+0.73 (+0.07%) ▲|NEE82.90+0.46 (+0.56%) ▲|NFLX77.06+1.05 (+1.37%) ▲|NKE36.94+0.32 (+0.87%) ▲|NOW132.97+1.80 (+1.37%) ▲|NVDA219.32+0.96 (+0.44%) ▲|ORCL152.94+0.00 (+0.00%) ▲|PEP137.04+0.39 (+0.29%) ▲|PFE27.61-0.05 (-0.16%) ▼|PG145.39+2.42 (+1.69%) ▲|PLTR167.09+1.23 (+0.74%) ▲|PM193.15+3.38 (+1.78%) ▲|QCOM185.31+8.43 (+4.76%) ▲|RTX198.37+0.25 (+0.13%) ▲|SBUX99.00-0.22 (-0.22%) ▼|SCHW106.81-0.53 (-0.49%) ▼|SO88.01+0.26 (+0.30%) ▲|SPG205.14+0.47 (+0.23%) ▲|T26.16+0.61 (+2.39%) ▲|TMO612.04+8.86 (+1.47%) ▲|TMUS183.56+6.40 (+3.61%) ▲|TSLA366.21+2.65 (+0.73%) ▲|TXN271.95+13.13 (+5.07%) ▲|UBER71.92-0.64 (-0.88%) ▼|UNH378.35-9.93 (-2.56%) ▼|UNP284.26-1.53 (-0.53%) ▼|UPS100.12+0.15 (+0.15%) ▲|USB62.83+0.42 (+0.67%) ▲|V371.12+3.91 (+1.06%) ▲|VZ50.63+0.66 (+1.32%) ▲|WFC90.52+1.07 (+1.19%) ▲|WMT106.62+0.89 (+0.84%) ▲|XOM165.55+0.32 (+0.19%) ▲|
26.7 C
New York
Friday, September 11, 2026

Tag: rates

newssourceFORcompanyinformationcontent1releasesmarket

AI Tools That Talk, Scan, and Save Lives Are Reshaping the Investment Landscape

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 20, 2025 /CNW/ -- Equity Insider News Commentary – Amid the wave of new...

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

– If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors –

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.3,4 A final decision on the approval in the European Union is expected in the coming months.

Analyzing Annuity Costs: A Detailed Breakdown for Strategic Financial Planning

Annuities, while potentially beneficial under certain circumstances, require careful scrutiny due to their associated costs. The primary concern is the substantial fees that can...

Fed Maintains Interest Rates—Evaluate Implications for Credit Cards, Auto Loans, Mortgages

The Federal Reserve's decision to maintain the current interest rate reflects a strategic pause amid an evolving economic landscape. Given President Trump's calls for...

Oil Tanker Bumps Near Hormuz—Panic Ensues, Because Why Not?

Ah, the Strait of Hormuz, where oil and geopolitics tango in a never-ending waltz of chaos. This week’s episode features a delightful collision of...

TikTok Engagement Metrics Rise: Analyzing Regulatory Impact on Market Projections

Six months ago, TikTok faced a critical juncture in the U.S. market, threatened by a Supreme Court ruling enforcing a divestiture from ByteDance or...

Evaluating IRR: Analyzing Potential Misrepresentations in Private Equity Returns

Private equity firms frequently employ IRR manipulation to embellish performance metrics. This tactic distorts reality, compelling UK regulators to intervene for investor protection. The...

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Elevance Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ELV

NEW YORK, June 19, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Elevance Health, Inc. (NYSE: ELV) between April 18, 2024 and October 16, 2024, both dates inclusive (the “Class Period”), of the important July 11, 2025 lead plaintiff deadline.

Court Grants Final Order to Lumina Gold Approving Arrangement with CMOC

VANCOUVER, BC, June 19, 2025 /CNW/ - Lumina Gold Corp. (TSXV: LUM) (OTCQB: LMGDF) (the "Company" or "Lumina") is pleased to announce that the Supreme Court of...

Court Grants Final Order to Lumina Gold Approving Arrangement with CMOC

VANCOUVER, BC, June 19, 2025 /PRNewswire/ - Lumina Gold Corp. (TSXV: LUM) (OTCQB: LMGDF) (the "Company" or "Lumina") is pleased to announce that the Supreme Court of...

Artemis Gold Announces Management Changes

TSXV: ARTG VANCOUVER, BC, June 19, 2025 /CNW/ - Artemis Gold Inc. (TSXV: ARTG) ("Artemis Gold" or the "Company") is pleased to announce the following...

ELSE NUTRITION ANNOUNCES DELAY IN FILING FINANCIAL STATEMENTS AND EXTENSION OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

VANCOUVER, BC, June 19, 2025 /PRNewswire/ - ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL) (the "Company") announces that the Company's principal regulator in...

New Study Data on Chemo-Immunotherapy Approach Using the ELIAS Cancer Immunotherapy (ECI®) to Treat Bone Cancer in Dogs Demonstrates Improved Outcomes

LENEXA, Kan., June 19, 2025 /PRNewswire/ -- ELIAS Animal Health, a leading companion animal cancer therapeutics company, today announced interim results from an ongoing clinical...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRates

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers